Ascendis Pharma A/S
ASND•NASDAQ•Healthcare•Biotechnology

About Ascendis Pharma A/S

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJan Mikkelsen
Founded2006
IPO DateJanuary 28, 2015
Employees1,017
CountryDenmark
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyEUR - EUR
TypeStock

Contact Information

Websiteascendispharma.com
Phone45 70 22 22 44
Address
Tuborg Boulevard 12 Hellerup, 2900 Denmark

Corporate Identifiers

CIK0001612042
CUSIP04351P101
ISINUS04351P1012
SIC2834

Leadership Team & Key Executives

Jan Moller Mikkelsen
President, Chief Executive Officer, Member of Executive Board and Executive Director
Scott T. Smith
Chief Financial Officer, Executive Vice President and Member of Executive Board
Pedersen Anni Lotte Kirstine Sonderbjerg
Executive Vice President, Chief Administrative Officer and Member of the Executive Board
Michael Wolff Jensen L.L.M.
Executive Vice President, Chief Legal Officer and Member of the Executive Board
Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Chad Fugure
Vice President of Investor Relations
Flemming Steen Jensen
Executive Vice President of Product Supply and Quality
Dr. Kennett Sprogoe Ph.D.
Executive Vice President and Head of Research and Product Development
Dr. Stina Singel M.D., Ph.D.
Executive Vice President and Head of Clinical Development for Oncology
Joseph Kelly
Head of U.S. Commercial of Endocrinology